Shares of Reliance Industries Ltd extended its rally for the seventh consecutive day on Thursday and its market valuation crossed the Rs 14 lakh crore mark. The market heavyweight stock has jumped 12.
New infections in India held near the lowest level since early April, as the country ordered 300 million vaccine doses from local manufacturer Biological-E. Japan led contributions totaling $2.4 billion aimed at closing a funding gap that has hampered the distribution of doses to poorer nations.
URL copied
A health worker administers a dose of the Covid-19 vaccine to a benificiary, in Bengaluru.
Reliance Industries Ltd s R&D arm has proposed the use of Niclosamide - the drug used to treat tapeworm infestation - for treating COVID-19 patients.
Niclosamide, a drug on the World Health Organisation s list of essential medicines, has been used to treat tapeworm infestation for more than 50 years.
The oral antiviral drug was also used to treat patients during the SARS outbreak of 2003-04. The company submitted a proposal for the application of Niclosamide as a potential drug against COVID-19, the firm s latest annual report said. The drug regulator will now evaluate the proposal for public use.